Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Susan M. Clardy
Observed names:
Susan Clardy,
Susan M Clardy
Observed institutions:
Harvard University,
Massachusetts General Hospital,
Center for Systems Biology,
Mersana Therapeutics (United States),
Syracuse University
ORCID:
0000-0002-0525-8903
Observed ORCID:
0000-0002-0525-8903
OpenAlex ID:
A5015303673
Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy
2017
·
Katherine S. Yang
, Hyungsoon Im
, et al.
·
Science Translational Medicine
·
278
PDF
Vitamin B12in drug delivery: breaking through the barriers to a B12bioconjugate pharmaceutical
2010
·
Susan M Clardy
, Damian G Allis
, et al.
·
Expert Opinion on Drug Delivery
·
102
Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells
2014
·
Wenxian Fu
, Julia Farache
, et al.
·
eLife
·
83
Dolaflexin: A Novel Antibody–Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect
2021
·
Aleksandr V. Yurkovetskiy
, Natalya D. Bodyak
, et al.
·
Molecular Cancer Therapeutics
·
76
In Vivo Imaging of GLP-1R with a Targeted Bimodal PET/Fluorescence Imaging Agent
2014
·
Christian Brand
, Dalya Abdel-Atti
, et al.
·
Bioconjugate Chemistry
·
58
PDF
Fluorescent Exendin-4 Derivatives for Pancreatic β-Cell Analysis
2013
·
Susan M. Clardy
, Edmund J. Keliher
, et al.
·
Bioconjugate Chemistry
·
41
Abstract 3503: XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab
2022
·
Jeremy R. Duvall
, Raghida A. Bukhalid
, et al.
·
Cancer Research
·
29
Abstract 6706: Systemic administration of STING agonist antibody-drug conjugates elicit potent anti-tumor immune responses with minimal induction of circulating cytokines
2020
·
Raghida A. Bukhalid
, Jeremy R. Duvall
, et al.
·
Cancer Research
·
26
Abstract 1738: XMT-2056, a well-tolerated, Immunosynthen-based STING-agonist antibody-drug conjugate which induces anti-tumor immune activity
2021
·
Jeremy R. Duvall
, Raghida A. Bukhalid
, et al.
·
Cancer Research
·
25
Rapid, high efficiency isolation of pancreatic ß-cells
2015
·
Susan M. Clardy
, James F. Mohan
, et al.
·
Scientific Reports
·
19
PDF
Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2023
·
Susan M. Clardy
, Alex Uttard
, et al.
·
Molecular Cancer Therapeutics
·
11
Abstract 2894: XMT-1592, a site-specific Dolasynthen-based NaPi2b-targeted antibody-drug conjugate for the treatment of ovarian cancer and lung adenocarcinoma
2020
·
Shawn Fessler
, Anouk Dirksen
, et al.
·
Cancer Research
·
11
Abstract 754: Unique pharmacologic properties of Dolaflexin-based ADCs—a controlled bystander effect
2018
·
Susan M. Clardy
, Alex Yurkovetskiy
, et al.
·
Cancer Research
·
9
Determining the Stoichiometry of a Protein–Polymer Conjugate Using Multisignal Sedimentation Velocity Analytical Ultracentrifugation
2021
·
Susan M. Clardy
, David H. Lee
, et al.
·
Bioconjugate Chemistry
·
8
Abstract 2114: Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potent anti-tumor activity by delivering STING agonist specifically to tumor cells andFcγRI-expressing subset of myeloid cells
2022
·
Naniye Malli Cetinbas
, Kalli C. Catcott
, et al.
·
Cancer Research
·
6
Abstract 907: XMT-1660, a B7-H4-targeted Dolasynthen antibody-drug conjugate for the treatment of breast cancer
2021
·
Shawn P. Fessler
, Jason Wang
, et al.
·
Cancer Research
·
3
Abstract 1773: Tumor cell-intrinsic STING pathway activation leads to robust induction of Type III Interferons and contributes to the anti-tumor activity elicited by STING agonism
2021
·
Naniye Malli Cetinbas
, Travis Monnell
, et al.
·
Cancer Research
·
3
620 Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates
2020
·
Naniye Malli Cetinbas
, Travis Monnell
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
Two-photon imaging of pancreatic beta cells in real time in vivo
2016
·
Susan M. Clardy
, Rainer H. Kohler
, et al.
·
TECHNOLOGY
·
2
Abstract 2687: Dolasynthen–a novel, homogeneous Auristatin F hydroxypropyl amide antibody-drug conjugate platform
2019
·
Dorin Toader
, Marc Damelin
, et al.
·
Cancer Research
·
1
Site-Specific Bioconjugation in Antibody−Drug Conjugates: From Conjugation Chemistry to Precision Molecular Design
2026
·
Ravi V. J. Chari
, Chuan Shen
, et al.
·
Journal of Medicinal Chemistry
Table S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024
·
Susan M. Clardy
, Alex Uttard
, et al.
PDF
Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024
·
Susan M. Clardy
, Alex Uttard
, et al.
PDF
Supplemental Data File 1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024
·
Susan M. Clardy
, Alex Uttard
, et al.
PDF
Supplemental Data File 1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
2024
·
Susan M. Clardy
, Alex Uttard
, et al.
Show more works
View as search
Works count:
50
Citation count:
804
H-index:
11
I10-index:
13
Year
Topic
Type
